Imara
United States
88 articles with Imara
-
Imara Announces Stockholder Approval of Merger With Enliven
2/22/2023
Imara Inc. announced the results of the special meeting of its stockholders held on February 22, 2023.
-
Enliven Therapeutics and Imara will merge in an all-stock deal to form a precision oncology company. The new entity will operate under the name Enliven Therapeutics.
-
Weeks after Imara announced its plans to discontinue the development of tovinontrinein for sickle cell and beta-thalassemia and heart failure, the company has culled 83% of its workforce.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Imara stock plunged 40% after announcing the failure of Phase II sickle cell and beta-thalassemia trials and plans to discontinue development.
-
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
4/5/2022
Imara Inc. announced results from interim analyses of its Ardent Phase 2b clinical trial of tovinontrine in patients with sickle cell disease and Forte Phase 2b clinical trial of tovinontrine in patients with beta-thalassemia.
-
Imara Reports Full Year 2021 Financial Results and Business Highlights
3/15/2022
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today reported financial results for the year ended December 31, 2021 and reviewed recent business highlights.
-
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Imara Inc. announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
1/25/2022
Imara Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687).
-
Shares of Mustang Bio have fallen more than 13% in premarket trading after announcing the FDA had placed a hold on the company’s Investigational New Drug application for its bubble boy gene therapy.
-
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
1/5/2022
Imara Inc. announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
12/14/2021
Imara Inc. (Nasdaq: IMRA), today announced the presentation of data from its nuclear factor erythroid 2-related factor 2 (Nrf2) activator program, IMR-261, at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.
-
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
12/13/2021
Imara Inc today announced the presentation of 12-month data from its Phase 2a open-label extension (OLE) trial for tovinontrine (IMR-687) as a potential treatment for sickle cell disease (SCD) at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.
-
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
11/22/2021
Imara Inc. (Nasdaq: IMRA), today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA).
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
11/16/2021
Imara Inc. (Nasdaq: IMRA), today announced data from a pre-specified interim analysis from its ongoing Forte Phase 2b clinical trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia.
-
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
11/9/2021
Imara Inc. today reported financial results for the third quarter ending September 30, 2021 and reviewed recent business highlights.
-
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
11/8/2021
Imara Inc. (Nasdaq: IMRA), announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687).